Therapies with CCL25 require controlled release via microparticles to avoid strong inflammatory reactions
Abstract Background Chemokine therapy with C–C motif chemokine ligand 25 (CCL25) is currently under investigation as a promising approach to treat articular cartilage degeneration. We developed a delayed release mechanism based on Poly (lactic-co-glycolic acid) (PLGA) microparticle encapsulation for...
Main Authors: | J. Spinnen, K. Fröhlich, N. Sinner, M. Stolk, J. Ringe, L. Shopperly, M. Sittinger, T. Dehne, M. Seifert |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Journal of Nanobiotechnology |
Online Access: | https://doi.org/10.1186/s12951-021-00830-7 |
Similar Items
-
Dose-Dependent Effect of Mesenchymal Stromal Cell Recruiting Chemokine CCL25 on Porcine Tissue-Engineered Healthy and Osteoarthritic Cartilage
by: Luise Lüderitz, et al.
Published: (2018-12-01) -
Chemokine CCL25 Induces Migration and Extracellular Matrix Production of Anulus Fibrosus-Derived Cells
by: Stefan Stich, et al.
Published: (2018-07-01) -
A Novel Method Facilitating the Simple and Low-Cost Preparation of Human Osteochondral Slice Explants for Large-Scale Native Tissue Analysis
by: Jacob Spinnen, et al.
Published: (2021-06-01) -
Investigation of the plasma levels of CCL-17 and CCL-25 and their receptor gene expression in rheumatoid arthritis patients
by: Samimi Z, et al.
Published: (2019-07-01) -
PLGA-Based Microparticles for the Sustained Release of BMP-2
by: Maria A. Woodruff, et al.
Published: (2011-03-01)